News | News By Subject | News by Disease News By Date | Search News

Lung cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
The FDA Calls Pfizer (PFE)’s Next-Generation Lung Cancer Drug a Breakthrough     4/27/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed     4/26/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study     4/18/2017
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline     3/23/2017
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals     3/22/2017
Genentech (RHHBY)'s $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire     2/8/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index     12/19/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study     10/10/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status     10/5/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle     9/23/2016
FDA Grants Priority Review and Breakthrough Tag for Merck & Co. (MRK)’s Keytruda     9/7/2016
Genentech (RHHBY)'s Tecentriq Shows Positive Data in Phase III Trial, Has an Upcoming Action Date in October     9/2/2016
Merck & Co. (MRK)'s Keytruda May Have an Edge Over Bristol-Myers Squibb (BMY)'s Opdivo for Cancer Doctors     8/26/2016
AstraZeneca PLC (AZN)'s Lung Cancer Drug Flunks Late-Stage Test     8/10/2016

News from Around the Web
New Blood Test Could Treat Non-Small-Cell Lung Cancer Faster, The Journal of Molecular Diagnostics Reveals     4/19/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
Liquid Biopsy For Lung Cancer Provides Rapid Results At Low Cost And No Trauma, Stanford University Study     1/6/2017
Czech Scientists Develop Human Lung Model To Aid Treatments, Brno University Of Technology Study     11/29/2016
Balance Of Power Shifts With Merck & Co. (MRK)'s Keytruda First-Line Therapy Approval In Lung Cancer     10/26/2016
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer     10/19/2016
AI Beats Doctors At Visual Diagnosis, Observes Many Times More Lung Cancer Signals, Stanford University Study     8/19/2016
Transgenomic, Inc. (TBIO) Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer     7/25/2016
University of Louisville Teams Up With Company To Help Lung Cancer Diagnosis     6/15/2016
This Diet Ups Your Lung Cancer Even If You Don't Smoke, MD Anderson Cancer Center Study     3/9/2016
Biotech Startup Yihuo Bio To Produce New Device For Early Detection Of Lung Cancer     2/29/2016
Could A Lung Cancer Drug Work Better With Coke? Erasmus MC Study     2/16/2016
This Lung Cancer Drug May Not Be What It Seems, Chemists Say     1/4/2016
Study Suggests Indi's Xpresys Test Could Reduce Invasive Procedures In NSCLC Diagnosis     12/23/2015
A New Way To Test For Rejection or Infection Following Lung Transplantation, Stanford University Study     10/15/2015

Press Releases
Study In Nature Shows Early Relapse Detection In Lung Cancer Using Natera's Technology For ctDNA Analysis     4/27/2017
First Patient Treated In Turnstone Biologics's Lung Cancer Trial Combining Novel Viral Cancer Therapy With Approved Checkpoint Inhibitor     4/26/2017
TRANSGENE (ENX:TNG) And Bristol-Myers Squibb (BMY) Announce Clinical Research Collaboration To Evaluate TG4010 In Combination With Opdivo And Standard Chemotherapy In First Line Non-Small Cell Lung Cancer     4/25/2017
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC)     4/24/2017
New Blood Test Could Treat Non-Small-Cell Lung Cancer Faster, The Journal of Molecular Diagnostics Reveals     4/19/2017
Genentech (RHHBY)’s Alecensa Superior To Pfizer (PFE)'s Crizotinib In Late-Stage Lung Cancer Trial     4/10/2017
Chugai Pharma's Alecensa Met Its Primary Endpoint In The ALEX Study     4/10/2017
Phase III Study Shows Genentech (RHHBY)’s Alecensa Was Superior To Crizotinib In A Specific Type Of Lung Cancer     4/10/2017
Immunomedics (IMMU) Catches a Break With Positive Mid-Stage Lung Cancer Data     4/5/2017
Indian FDA Approves The First Autologous Dendritic Cell-Based Immuno-Oncology Product, APCEDEN     4/5/2017
DelMar Pharma Provides VAL-083 Updates From The Ongoing AACR Annual Meeting     4/5/2017
New Data Show Biodesix, Inc.’s VeriStrat Test Is Cost-Saving, Improves Survival And Quality Of Life In Advanced Lung-Cancer Patients     4/4/2017
Genprex Reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect Of TUSC2 In Combination With PD-1 Checkpoint Blockade In Lung Cancer     4/3/2017
Bristol-Myers Squibb (BMY) Release: Five-Year Survival Observed With Opdivo (Nivolumab) In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), In Phase 1 Study CA209-003     4/3/2017
Bristol-Myers Squibb (BMY) And Incyte (INCY) To Advance The Combination Of Opdivo (Nivolumab) And Epacadostat Into First-Line Registrational Trials     4/3/2017

//-->